New: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

4th April, 2019, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published an update to a set of recommendations for the management of systemic lupus erythematosus. The recommendations report on emerging new evidence and expert opinion made since the first EULAR Recommendations on systemic lupus erythematosus were published in 2008.

Treatment in Systemic Lupus Erythematosus (SLE) aims at remission or low disease activity and prevention of flares. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE.

A systematic literature review was performed, followed by the modified Delphi method, which was used to form questions, elicit expert opinions and reach consensus. The methods/methodological approach included pharmacologic treatment of SLE; management of specific manifestations; monitoring SLE and treatment targets; comorbidities and adjunct therapy.

Based on the evidence and expert opinion from an international task force, overarching principles and recommendations were formulated. Four overarching principles and 13 recommendations were agreed upon. The four overarching principles are:

- SLE is a multisystem disease - occasionally limited to one or few organs - diagnosed on clinical grounds in the presence of characteristic serologic abnormalities.
- SLE care is multidisciplinary, based on a shared patient-physician decision, and should consider individual, medical and societal costs.
- Treatment of organ-/life-threatening SLE includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses.
- Treatment goals include long-term patient survival, prevention of organ damage and optimisation of health-related quality of life.

The recommendations are categorised into four parts:

1. Goals of treatment
2. Treatment of SLE (general)
3. Specific manifestations

The summary of recommendations in lay format are:

1. The goal of treatment in lupus is to control activity of the disease and prevent flares
2. All patients with SLE should receive hydroxychloroquine, with regular monitoring for eye toxicity
3. Glucocorticoids (GC, cortisone) can help to control symptoms when the disease is active. In the long-term its dose must not exceed 7.5 mg/day of prednisone.

4. Immunosuppressive drugs such as methotrexate, azathioprine and mycophenolate can be used to better control the disease and allow using less glucocorticoids.

5. When lupus cannot be controlled with the conventional drugs biologic drugs like belimumab or rituximab can be used.

6. Skin disease in lupus is initially treated with creams/ointments or hydroxychloroquine, with or without oral glucocorticoids. When these do not control the disease, immunosuppressives or biologics can be used.

7. Symptoms involving the brain and nervous system are not always due to lupus. When caused by lupus, immunosuppressive drugs or aspirin/anticoagulants are used.

8. Severe drops in platelets or low blood counts from SLE are treated with GC and immunosuppressive drugs; in case of relapses, rituximab should be considered.

9. Biopsy of the kidney is essential to diagnose kidney involvement in lupus. Immunosuppressive drugs of first-choice are mycophenolate mofetil and cyclophosphamide.

10. A second kidney biopsy may be considered in cases of incomplete response after one year of treatment.

11. Patients with lupus should be tested for antiphospholipid antibodies, because the latter are associated with blood clots (thrombosis), pregnancy losses and other complications such as strokes.

12. Patients with SLE have an increased risk for infections and should be vaccinated against influenza and pneumococcus, as well as human papilloma virus (adolescents).

13. Patients with SLE may suffer more from heart attacks and strokes. To decrease the risk for these complications, quitting smoking, and control of high blood pressure, dyslipidaemia, diabetes are essential.

The level of evidence, grade of recommendation and level of agreement were allocated to each statement.

Systemic lupus erythematosus (SLE) has variable presentation, course and prognosis. The wide acceptance and popularity of the first EULAR recommendations for its management, published in 2008, prompted the subsequent development of specific recommendations regarding monitoring, neuropsychiatric and renal disease, as well as for pregnancy and women’s health in lupus. Since these publications, new data have emerged on treatment strategies and validated goals of treatment, alternative regimens of glucocorticoids (GC), ‘multitargeted’ therapy with the use of calcineurin inhibitors (CNIs) in lupus nephritis (LN), and the approval of the first biological therapy for SLE. These advances called for an update of the EULAR recommendations for lupus, capitalising on the strengths of, and experience from the previous projects.

About EULAR

The European League against Rheumatism (EULAR) is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of
rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.

To find out more about the activities of EULAR, visit: www.eular.org.

Contact
Dr. Julia Rautenstrauch, EULAR Executive Director, julia.rautenstrauch@eular.org, Tel. +41 44 716 30 31

Notes to Editors
EULAR Recommendations: https://www.eular.org/recommendations_management.cfm
Follow EULAR on Twitter, Facebook, Instagram, Youtube and LinkedIn.

+++ ENDS +++